Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ototoxicity 1Heart Failure 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Cardiovascular Diseases 1Cardiotoxicity 1Atherosclerosis 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Letrozole 221Capecitabine 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 132Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all
NCT03971019 2019-08-14

SBSBC

Peking Union Medical College Hospital

Phase 3 Unknown
314 enrolled
Breast

Breast Neoplasms

NCT00914017 2010-02-11

Statins and Breast Cancer Biomarkers

University of Vermont

Phase 2 Unknown
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡